Advances in surgical techniques, perioperative management, and immunosuppressive therapies (ISs) have significantly improved the clinical outcomes of liver transplantation (LT). However, these advancements have also highlighted the importance of addressing non-hepatic complications, particularly cardiovascular events (CVEs), in the management of LT patients. Key risk factors for CVEs in post-LT patients include metabolic conditions such as diabetes mellitus (DM), hypertension (HTN), and dyslipidemia. The continued need for ISs contributes to the development of these metabolic complications, making their management crucial for optimizing patient outcomes. This review aims to summarize current strategies for managing metabolic complications, including DM, HTN, and dyslipidemia, in post-LT patients.